Therefore, phenotype severity of LMNA-related DCM may depend on sex hormone levels and inhibition of the androgen receptor‒SRF‒FHL2 complex may provide a potential therapeutic benefit [121]. Here, FHL2 is linked to familial dilated cardiomyopathy.